NCT04232514
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects
A Open-label, Single Center Drug Interaction Study Between HEC74647PA Capsule and HEC110114 in Healthy Subjects
Sunshine Lake Pharma Co., Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Chronic Hepatitis C
- Drug/Device/Intervention
- HEC74647
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Sunshine Lake Pharma Co., Ltd.
- Location
- Changchun, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jul 15, 2020
- End date
- Aug 22, 2020
- Enrollment
- 28 participants
Primary outcome
Adverse Events,Cmax,AUC
Summary
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics
 (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects
ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04232514
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04232514 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.